136 related articles for article (PubMed ID: 15100376)
21. Absence of the Effect of Pretransplant Body Mass Index on Post Kidney Transplant Outcomes.
Tremblay S; Kaiser TE; Alloway RR; Woodle ES; Diwan TS
Prog Transplant; 2016 Jun; 26(2):183-90. PubMed ID: 27207408
[TBL] [Abstract][Full Text] [Related]
22. Conversion therapy to everolimus in renal transplant recipients: results after one year.
Giron F; Baez Y; Niño-Murcia A; Rodríguez J; Salcedo S
Transplant Proc; 2008 Apr; 40(3):711-3. PubMed ID: 18454994
[TBL] [Abstract][Full Text] [Related]
23. Anemia after renal transplantation: an underestimated problem.
Ott U; Busch M; Steiner T; Wolf G
Transplant Proc; 2008 Dec; 40(10):3481-4. PubMed ID: 19100418
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Posttransplantation Anemia.
Unagami K; Okumi M; Tamura T; Ishida H; Tanabe K; Nitta K
Contrib Nephrol; 2018; 195():92-101. PubMed ID: 29734154
[TBL] [Abstract][Full Text] [Related]
25. Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors.
Shah N; Al-Khoury S; Afzali B; Covic A; Roche A; Marsh J; Macdougall IC; Goldsmith DJ
Transplantation; 2006 Apr; 81(8):1112-8. PubMed ID: 16641595
[TBL] [Abstract][Full Text] [Related]
26. Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease.
Morales JM; Marcén R; Andrés A; Molina MG; Castillo DD; Cabello M; Capdevila L; Campistol JM; Oppenheimer F; Serón D; Vernet SG; Lampreave I; Valdés F; Anaya F; Escuín F; Arias M; Pallardó L; Bustamante J
Kidney Int Suppl; 2008 Dec; (111):S94-9. PubMed ID: 19034336
[TBL] [Abstract][Full Text] [Related]
27. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
[TBL] [Abstract][Full Text] [Related]
28. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen.
Sampaio EL; Pinheiro-Machado PG; Garcia R; Felipe CR; Park SI; Casarini DE; Moreira S; Franco MF; Tedesco-Silva H; Medina-Pestana JO
Clin Transplant; 2008; 22(2):141-9. PubMed ID: 18339132
[TBL] [Abstract][Full Text] [Related]
29. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
[TBL] [Abstract][Full Text] [Related]
30. Pediatric renal transplantation: a single-center experience in northeast Thailand.
Wisanuyotin S; Jiravuttipong A
J Med Assoc Thai; 2009 Dec; 92(12):1635-9. PubMed ID: 20043566
[TBL] [Abstract][Full Text] [Related]
31. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G
Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338
[TBL] [Abstract][Full Text] [Related]
32. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
[TBL] [Abstract][Full Text] [Related]
33. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
Araki M; Flechner SM; Ismail HR; Flechner LM; Zhou L; Derweesh IH; Goldfarb D; Modlin C; Novick AC; Faiman C
Transplantation; 2006 Feb; 81(3):335-41. PubMed ID: 16477217
[TBL] [Abstract][Full Text] [Related]
34. Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients.
Cuervas-Mons V; Herrero JI; Gomez MA; González-Pinto I; Serrano T; de la Mata M; Fabregat J; Gastaca M; Bilbao I; Varo E; Sánchez-Antolín G; Rodrigo J; Espinosa MD
Clin Transplant; 2015 Aug; 29(8):667-77. PubMed ID: 25924549
[TBL] [Abstract][Full Text] [Related]
35. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
[TBL] [Abstract][Full Text] [Related]
36. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
[TBL] [Abstract][Full Text] [Related]
37. The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60.
Xenos EX; Ciancio G; Burke GW; Roth D; Miller J
Clin Transplant; 1997 Oct; 11(5 Pt 2):497-9. PubMed ID: 9361949
[TBL] [Abstract][Full Text] [Related]
38. Anemia and Immunosuppressive Regimen in Renal Transplanted Patients: Single-Center Retrospective Study.
Carta P; Bigazzi B; Buti E; Antognoli G; Di Maria L; Caroti L; Minetti EE
Transplant Proc; 2016 Mar; 48(2):337-9. PubMed ID: 27109950
[TBL] [Abstract][Full Text] [Related]
39. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
[TBL] [Abstract][Full Text] [Related]
40. Clinical risk factors associated with the post-transplant anemia in kidney transplant patients.
Chang Y; Shah T; Min DI; Yang JW
Transpl Immunol; 2016 Sep; 38():50-3. PubMed ID: 27485477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
